Ganirelix structure
|
Common Name | Ganirelix | ||
---|---|---|---|---|
CAS Number | 124904-93-4 | Molecular Weight | 1570.32000 | |
Density | 1.31 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C80H113ClN18O13 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of GanirelixGanirelix is a competitive and selective gonadotropin releasing hormone (GnRH) antagonist. Ganirelix prevents endogenous GnRH from inducing luteinising hormone (LH) and follicle stimulating hormone relea[1]. |
Name | ganirelix |
---|
Description | Ganirelix is a competitive and selective gonadotropin releasing hormone (GnRH) antagonist. Ganirelix prevents endogenous GnRH from inducing luteinising hormone (LH) and follicle stimulating hormone relea[1]. |
---|---|
Related Catalog | |
In Vivo | Ganirelix (0.1 mg/kg; s.c.; daily for 14 d) reduces luteinising hormone levels in female rats[2]. Animal Model: Female Sprague-Dawley rats, weighing 225–300 mg[2] Dosage: 0.1 mg/kg Administration: Subcutaneous injection, daily for 14 d Result: Reduced luteinising hormone levels. |
References |
[1]. Gillies PS, et al. Ganirelix. Drugs. 2000 Jan;59(1):107-11; discussion 112-3. |
Density | 1.31 g/cm3 |
---|---|
Molecular Formula | C80H113ClN18O13 |
Molecular Weight | 1570.32000 |
Exact Mass | 1568.84000 |
PSA | 451.49000 |
LogP | 7.99260 |